Cancer
Colorado drug takes aim at cancer metastasis
Credit: University of Colorado Cancer Center Many cancers are relatively harmless at their site of origin, and it is only...
Estrogen byproducts linked to survival in breast cancer patients
Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center found preliminary evidence that measuring byproducts of the hormone...
HDAC inhibition may combat resistance to anti-PD-1 therapy in patients with melanoma
ATLANTA -- A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed clinical...
Researchers discover how tumor-killing immune cells attack lymphomas in living mice
Credit: Cazaux et al., 2019 In a study that will be published April 1 in the Journal of Experimental Medicine,...
Gilteritinib improved survival for patients with acute myeloid leukemia
ATLANTA -- Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia...
Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome
ATLANTA -- Vaccination with as few as four tumor antigens generated antigen-specific responses, reduced intestinal tumors, and improved survival in...
Umbralisib shows early promise for patients with marginal zone lymphoma
ATLANTA -- The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients with...
Data from two KEYNOTE trials show pembrolizumab benefited patients with advanced SCLC
ATLANTA -- The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced...
Targeted drug for leukemia tested at Penn Medicine helps patients live longer
Data presented at AACR Annual Meeting on recently approved drug that targets common mutation in AML ATLANTA - An inhibitor...
CD40 combination therapy can shrink pancreatic tumors
Study results to be presented during a plenary session at AACR Annual Meeting ATLANTA - A new combination of immunotherapy...
Excess body weight before 50 is associated with higher risk of dying from pancreatic cancer
ATLANTA --Excess weight before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess weight at...
Pancreatic Cancer Collective funds two AI teams to identify high-risk populations
Computational tools seek to identify pancreatic cancer earlier, provide more opportunities for timely, effective treatmentsCredit: Pancreatic Cancer Collective (ATLANTA -...
Immunotherapy combination effective for patients with rare neuroendocrine cancer
Credit: Hope Foundation for Cancer Research A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to...
Adding savolitinib to osimertinib beneficial for certain pretreated lung cancer patients
ATLANTA -- Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients who...
Immune checkpoint inhibitor combo efficacious for patients with neuroendocrine carcinoma
ATLANTA -- A combination of the anti-CTLA-4 immunotherapeutic ipilimumab (Yervoy) and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit among...
HER2-targeted CAR T-cell therapy shows promising antitumor activity in patients with sarcoma
ATLANTA -- A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was...
Mesothelin-targeted CAR T-cell therapy shows early promise in patients with solid tumors
ATLANTA -- A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity...
Genomic analysis offers roadmap for diagnosis and treatment of a high-risk leukemia
An international collaboration led by St. Jude Children's Research Hospital reveals the genomic basis of acute erythroid leukemia, an aggressive...
Screening for colorectal cancer at 45 would avert deaths, but testing older adults would do more
Starting routine colorectal cancer screening at age 45 rather than 50 would decrease U.S. cancer deaths by as much as...
Cancer prevention drug also disables H. pylori bacterium
Credit: Joe Howell A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than...
